These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16610768)

  • 21. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
    Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
    Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B.
    Michel ML; Loirat D
    Intervirology; 2001; 44(2-3):78-87. PubMed ID: 11509869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vaccine prophylaxis of viral hepatitis B in patients with acute leukemia].
    Gurina NM; Svedentsov EP; Shardakov VI; Cherepanova VV
    Ter Arkh; 2008; 80(7):27-9. PubMed ID: 18763590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.
    Wörns MA; Teufel A; Kanzler S; Shrestha A; Victor A; Otto G; Lohse AW; Galle PR; Höhler T
    Am J Gastroenterol; 2008 Jan; 103(1):138-46. PubMed ID: 17970833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Some questions to be raised about the hepatitis B vaccine.
    Poirriez J
    Vaccine; 2002 Mar; 20(13-14):1696-8. PubMed ID: 11906753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.
    Cooper CL; Davis HL; Morris ML; Efler SM; Adhami MA; Krieg AM; Cameron DW; Heathcote J
    J Clin Immunol; 2004 Nov; 24(6):693-701. PubMed ID: 15622454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III trial in hepatitis B prevention.
    AIDS Read; 2001 Feb; 11(2):85. PubMed ID: 11279887
    [No Abstract]   [Full Text] [Related]  

  • 29. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report.
    But DY; Lai CL; Lim WL; Fung J; Wong DK; Yuen MF
    Vaccine; 2008 Dec; 26(51):6587-91. PubMed ID: 18835318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness.
    de la Hoz F; Perez L; de Neira M; Hall AJ
    Int J Infect Dis; 2008 Mar; 12(2):183-9. PubMed ID: 17913535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A low rate of hepatitis B virus vaccine breakthrough infections in Mongolia.
    Ijaz S; Khulan J; Bissett SL; Ferns RB; Nymadawa P; Tedder RS
    J Med Virol; 2006 Dec; 78(12):1554-9. PubMed ID: 17063521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of a single dose hepatitis B depot vaccine.
    MacDonald LD; Fuentes-Ortega A; Sammatur L; Mansour M
    Vaccine; 2010 Oct; 28(44):7143-5. PubMed ID: 20832491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults.
    Hyer R; McGuire DK; Xing B; Jackson S; Janssen R
    Vaccine; 2018 May; 36(19):2604-2611. PubMed ID: 29628151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.
    Janssen JM; Jackson S; Heyward WL; Janssen RS
    Vaccine; 2015 Jul; 33(31):3614-8. PubMed ID: 26067185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination against hepatitis B in patients on chronic haemodialysis.
    Kovacic V
    Int J Clin Pract; 2003 Apr; 57(3):161-2. PubMed ID: 12723714
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunostimulatory DNA as a vaccine adjuvant.
    Higgins D; Marshall JD; Traquina P; Van Nest G; Livingston BD
    Expert Rev Vaccines; 2007 Oct; 6(5):747-59. PubMed ID: 17931155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies.
    Ni YH; Huang LM; Chang MH; Yen CJ; Lu CY; You SL; Kao JH; Lin YC; Chen HL; Hsu HY; Chen DS
    Gastroenterology; 2007 Apr; 132(4):1287-93. PubMed ID: 17433322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
    Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
    Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of the CpG Adjuvant 1018: A Case Study.
    Campbell JD
    Methods Mol Biol; 2017; 1494():15-27. PubMed ID: 27718183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose intradermal and subcutaneous versus intramuscular hepatitis B vaccination in primary non-responding hemodialysis patients.
    Sorkhi H; Dooki MR; Ebrahimnejad MS
    J Med Assoc Thai; 2006 Oct; 89(10):1648-53. PubMed ID: 17128839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.